source stringlengths 2 222 | date stringlengths 19 19 | url stringlengths 22 853 ⌀ | text stringlengths 0 10k ⌀ | title stringlengths 0 701 | context_id stringlengths 1 9 | document_id stringclasses 2
values | document_type stringclasses 2
values |
|---|---|---|---|---|---|---|---|
Zacks Investment Research | 2021-10-11 19:58:24 | https://www.zacks.com/stock/news/1809495/abbvie-abbv-dips-more-than-broader-markets-what-you-should-know | In the latest trading session, AbbVie (ABBV) closed at $110.34, marking a -0.76% move from the previous day. | AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-10-11 13:49:51 | https://www.zacks.com/stock/news/1809197/this-is-why-abbvie-abbv-is-a-great-dividend-stock | Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? | This is Why AbbVie (ABBV) is a Great Dividend Stock | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-10-11 08:42:00 | https://www.prnewswire.com/news-releases/allergan-aesthetics-launches-series-of-initiatives-to-support-breast-cancer-awareness-301396450.html | IRVINE, Calif., Oct. 11, 2021 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is continuing its commitment to breast health, awareness, restoration, and research in support of breast cancer awareness month. | Allergan Aesthetics Launches Series of Initiatives to Support Breast Cancer Awareness | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-10-10 15:59:16 | https://seekingalpha.com/article/4459262-my-dividend-growth-portfolio-september-update-time-to-start-buying-again | The portfolio targets 3% initial dividend yields and 7% dividend growth. Hybridizing companies is often used to reach the target. Income was boosted by several increases in September and is now projected at $13,605 for 2021. | My Dividend Growth Portfolio September Update: Time To Start Buying Again | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Pulse2 | 2021-10-10 10:48:11 | https://pulse2.com/abbvie-nyse-abbv-stock-why-it-increased-this-past-week/ | The shares of AbbVie Inc (NYSE: ABBV) increased this past week. This is why it happened. | ABBV Stock: Why It Increased This Past Week | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-10-10 09:15:00 | https://seekingalpha.com/article/4459214-upcoming-ex-dividend-dates-october-12-25-2021 | We provide a summary of upcoming ex-dividend dates in a quick reference table. The table includes relevant data and key statistics as well as the next payout and pay date. | Upcoming Ex-Dividend Dates: October 12-25, 2021 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-10-09 07:03:37 | https://seekingalpha.com/article/4459165-14-top-dividends-on-earth-ideal-prices-october | Kiplinger "insights for investors" online first offered a list of 91 "Top Dividend Stocks From Around The World" 7/13/20. Two Kiplinger articles provided this 102 Top Dividend Stocks list 7/1/21. 39 European “Dividend Aristocrats” showed 10 years of stable or increasing dividends; 65 S&P 500 Aristocrats showed 25 years... | Here's 14 Top Dividends On Earth At Ideal Prices For October | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-10-08 07:15:00 | https://seekingalpha.com/article/4458942-abbvie-vs-moderna-stock-better-buy | MRNA and ABBV have come under pressure over the last two months due to news items that could spell trouble. The two companies are very different when it comes to diversification, pipeline strength, and their respective two-year outlook. | AbbVie Vs. Moderna Stock: Which Is The Better Buy? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-10-07 10:30:00 | https://www.fool.com/investing/2021/10/07/why-abbvie-stock-sank-in-september/ | A regulatory setback weighed on the drugmaker's shares last month. | Why AbbVie Stock Sank in September | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-10-07 08:16:00 | https://www.prnewswire.com/news-releases/abbvies-upadacitinib-rinvoq-met-primary-and-most-ranked-secondary-endpoints-in-phase-3-study-for-non-radiographic-axial-spondyloarthritis-301395109.html | NORTH CHICAGO, Ill., Oct. 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from Study 2 of the Phase 3 SELECT-AXIS 2 clinical trial in adults with active non-radiographic axial spondyloarthritis (nr-axSpA), showing upadacitinib (RINVOQ®; 15 mg, once daily) met the primary endpoint o... | AbbVie's Upadacitinib (RINVOQ®) Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic Axial Spondyloarthritis | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-10-07 08:15:00 | https://www.prnewswire.com/news-releases/abbvies-rinvoq-upadacitinib-met-primary-and-all-ranked-secondary-endpoints-in-phase-3-study-in-ankylosing-spondylitis-301395108.html | NORTH CHICAGO, Ill., Oct. 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from the first of two studies of the Phase 3 SELECT-AXIS 2 clinical trial evaluating the efficacy and safety of RINVOQ® (upadacitinib; 15 mg, once daily) in patients with active ankylosing spondylitis (AS) wh... | AbbVie's RINVOQ® (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing Spondylitis | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2021-10-06 15:51:50 | https://www.gurufocus.com/news/1538895/vertex-needs-to-sell-or-make-a-big-acquisition | Should investors holding shares of Vertex Pharmaceuticals Incorporated ( VRTX , Financial) follow the axiom, “Good things come to those who wait?” | Vertex Needs to Sell or Make a Big Acquisition | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-10-05 05:05:02 | https://seekingalpha.com/article/4458461-abbvie-appears-ready-to-reverse-and-outperform | AbbVie Appears Ready To Reverse And Outperform | AbbVie Appears Ready To Reverse And Outperform | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-10-04 19:29:26 | https://www.zacks.com/stock/news/1804889/abbvie-abbv-stock-moves-0-33-what-you-should-know | AbbVie (ABBV) closed the most recent trading day at $108.73, moving -0.33% from the previous trading session. | AbbVie (ABBV) Stock Moves -0.33%: What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-10-04 08:42:00 | https://seekingalpha.com/article/4458315-dividend-increases-expected-in-october-2021 | Dividends are the foundation of our goal to reach financial freedom. Without growth, your dividend income stream will lose purchasing power to inflation. | Dividend Increases Expected In October 2021 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-10-02 09:30:00 | https://seekingalpha.com/article/4458129-upcoming-ex-dividend-dates-october-5-18-2021 | We provide a summary of upcoming ex-dividend dates in a quick reference table. The table includes relevant data and key statistics as well as the next payout and pay date. | Upcoming Ex-Dividend Dates: October 5-18, 2021 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-10-02 07:15:00 | https://www.fool.com/investing/2021/10/02/heres-what-warren-buffett-looks-for-with-healthcar/ | There's a reason why there are so few of them in his portfolio. | Here's What Warren Buffett Looks For With Healthcare Stocks | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-09-30 15:04:29 | https://www.benzinga.com/general/biotech/21/09/23177621/abbvie-presents-new-upadacitinib-data-in-atopic-dermatitis | AbbVie Inc (NYSE: ABBV) announced new analyses from the Phase 3 Rinvoq (upadacitinib) atopic dermatitis clinical trial program. Data were presented at the European Academy of Dermatology and Venereology (EADV) Virtual Congress. | AbbVie Presents New Upadacitinib Data In Atopic Dermatitis | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-09-30 15:02:31 | https://www.benzinga.com/general/biotech/21/09/23177323/abbvie-unveils-new-durable-risankizumab-data-in-psoriatic-arthritis | AbbVie Inc (NYSE: ABBV) announced new Phase 3 data analyses of KEEPsAKE-1 and KEEPsAKE-2, evaluating Skyrizi (risankizumab) in adults with active psoriatic arthritis for one year (52 weeks). The results were presented at the European Academy of Dermatology and Venereology (EADV) Virtual Congress. | AbbVie Unveils New Durable Risankizumab Data In Psoriatic Arthritis | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-09-30 14:57:41 | https://seekingalpha.com/article/4457879-buy-the-dip-on-these-3-dividend-gems-yielding-over-4-percent | As volatility increases, investors tend to shift their focus to strong dividend payers to help them weather the storm. | Buy The Dip On These 3 Dividend Gems Yielding Over 4% | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-09-30 09:45:00 | https://www.prnewswire.com/news-releases/abbvie-presents-late-breaking-data-on-risankizumab-skyrizi-in-psoriatic-arthritis-at-the-30th-european-academy-of-dermatology-and-venereology-eadv-congress-301388850.html | NORTH CHICAGO, Ill., Sept. 30, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today presented results from new Phase 3 data analyses of KEEPsAKE-1 and KEEPsAKE-2, evaluating risankizumab (SKYRIZI®, 150 mg) in adults with active psoriatic arthritis for one year (52 weeks).1 These results were featured during the "Late Breakin... | AbbVie Presents Late-Breaking Data on Risankizumab (SKYRIZI®) in Psoriatic Arthritis at the 30th European Academy of Dermatology and Venereology (EADV) Congress | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-09-29 11:15:06 | https://www.zacks.com/stock/news/1802536/abbvie-s-abbv-migraine-prevention-drug-qulipta-gets-fda-nod | The FDA approves AbbVie's (ABBV) Qulipta (atogepant) for preventive treatment of episodic migraine in adults. | AbbVie's (ABBV) Migraine Prevention Drug Qulipta Gets FDA Nod | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Schaeffers Research | 2021-09-29 10:02:34 | https://www.schaeffersresearch.com/content/news/2021/09/29/abbvie-stock-rises-after-fda-approves-3rd-headache-drug | The U.S. Food and Drug Administration (FDA) just approved AbbVie Inc's (NYSE:ABBV) migraine prevention treatment, marking the company's third drug in its roster for severe headaches. | AbbVie Stock Rises After FDA Approves 3rd Headache Drug | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-09-29 08:37:36 | https://www.benzinga.com/general/biotech/21/09/23150634/fda-gives-nod-to-first-oral-cgrp-receptor-to-prevent-migraine-from-abbvie | The FDA has approved AbbVie Inc's (NYSE: ABBV) Qulipta (atogepant) to prevent episodic migraines in adults. Qulipta is the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist specifically developed for the preventive treatment of migraine. | FDA Gives Nod To First Oral CGRP Receptor To Prevent Migraine From AbbVie | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-09-29 01:33:23 | https://seekingalpha.com/article/4457600-best-dividend-aristocrats-for-october-2021 | NOBL's momentum fades in September hindering its chances of having a record-breaking return this year. I present 3 strategies that theoretically can beat the dividend aristocrat index in the long term. | Best Dividend Aristocrats For October 2021 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-09-28 18:42:00 | https://www.prnewswire.com/news-releases/fda-approves-qulipta-atogepant-the-first-and-only-oral-cgrp-receptor-antagonist-specifically-developed-for-the-preventive-treatment-of-migraine-301387297.html | NORTH CHICAGO, Ill., Sept. 28, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved QULIPTA™ (atogepant) for the preventive treatment of episodic migraine in adults.1 QULIPTA is the first and only oral calcitonin gene-related peptide (CGRP) receptor antagoni... | FDA Approves QULIPTA™ (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2021-09-28 15:30:23 | https://investorplace.com/2021/09/7-biotech-stocks-entering-the-golden-boom-phase/ | These biotech stocks offer a more mature take on an otherwise risky sector. These companies already have successes under their belt. | 7 Biotech Stocks Entering the Golden Boom Phase | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-09-27 19:10:27 | https://www.zacks.com/stock/news/1801520/abbvie-abbv-gains-as-market-dips-what-you-should-know | In the latest trading session, AbbVie (ABBV) closed at $107.72, marking a +0.61% move from the previous day. | AbbVie (ABBV) Gains As Market Dips: What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-09-27 14:36:50 | https://seekingalpha.com/article/4457302-abbvie-is-a-cheap-large-cap | Before the takeover, AbbVie's business largely depended on one drug: Humira. But, the term of the patent for the drug in the United States will end in 2023. | AbbVie Is A Cheap Large Cap With New Drugs To Come | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-09-27 06:45:00 | https://www.fool.com/investing/2021/09/27/could-abbvies-new-collaboration-be-a-blockbuster/ | AbbVie recently announced a strategic partnership with Regenxbio for wet age-related macular degeneration and diabetic retinopathy treatment. | Could AbbVie's New Collaboration Be a Blockbuster? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-09-25 07:05:00 | https://seekingalpha.com/article/4456985-dividend-aristocrats-5-buys-and-5-sells | In a low-interest-rate environment where inflation is eating up the returns from bonds, going for income-paying equities seems like an opportune choice. Dividend Aristocrats could thus be attractive. Valuations should be considered, however, and some of these companies look overly expensive today, while others are trad... | Dividend Aristocrats: 5 Buys And 5 Sells | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-09-25 06:55:00 | https://www.fool.com/investing/2021/09/25/why-abbvie-just-made-a-18-billion-gene-therapy-dea/ | The big drugmaker wants another near-term growth driver. | Why AbbVie Just Made a $1.8 Billion Gene Therapy Deal | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-09-24 14:32:19 | https://seekingalpha.com/article/4456972-bme-defensive-healthcare-exposure-with-a-distribution-yield-of-5-percent | BME: Defensive Healthcare Exposure With A Distribution Yield Of ~5% | BME: Defensive Healthcare Exposure With A Distribution Yield Of ~5% | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-09-24 13:16:05 | https://www.benzinga.com/general/biotech/21/09/23091446/takeda-guilty-of-supply-contract-breach-with-abbvie-for-prostate-cancer-drug | In a spat between Takeda Pharmaceutical Co Ltd (NYSE: TAK) and AbbVie Inc (NYSE: ABBV) for Lupron (leuprorelin), a Delaware judge has issued a ruling in favor of AbbVie. The new ruling found that Takeda is guilty of breach of contract for failing to supply its partner with the prostate cancer drug. | Takeda Guilty Of Supply Contract Breach With AbbVie For Prostate Cancer Drug | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-09-24 04:10:08 | https://seekingalpha.com/article/4456867-welcoming-new-positions-abbvie-abbv-vici-properties | After last September 17th's option expiration, we are looking at new positions in ABBV and VICI. The general market weakness didn't help as it put pressure on share prices across the board, though it was about time for some volatility. | Welcoming New Positions In AbbVie And VICI Properties | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-09-23 23:45:39 | https://seekingalpha.com/article/4456847-abbvie-stock-4-9-percent-yielding-abbv-best-buffett-aristocrat-bargain | Warren Buffett became the greatest investor of all time thanks to disciplined financial science and a love of "wonderful companies at fair prices". Today 4.9% yielding AbbVie is Berkshire's 2nd biggest aristocrat holding, totaling over $2.3 billion. | 4.9% Yielding AbbVie Is The Best Buffett Aristocrat Bargain You Can Buy | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-09-23 08:45:00 | https://www.prnewswire.com/news-releases/abbvie-presents-new-data-analyses-for-growing-dermatology-portfolio-at-the-30th-european-academy-of-dermatology-and-venereology-eadv-congress-301383523.html | NORTH CHICAGO, Ill., Sept. 23, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will present 27 abstracts across its dermatology portfolio, including new analyses evaluating the safety and efficacy of RINVOQ® (upadacitinib) in atopic dermatitis and new data on SKYRIZI® (risankizumab) in psoriasis and psoriat... | AbbVie Presents New Data Analyses for Growing Dermatology Portfolio at the 30th European Academy of Dermatology and Venereology (EADV) Congress | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-09-23 06:03:00 | https://www.fool.com/investing/2021/09/23/3-relatively-safe-pharma-stocks-you-can-buy-right/ | These stocks should be less volatile than many of the alternatives. | 3 Relatively Safe Pharma Stocks You Can Buy Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
24/7 Wall Street | 2021-09-22 07:24:41 | https://247wallst.com/investing/2021/09/22/hedge-funds-dump-stocks-move-to-these-5-big-dividend-winners-now/ | While we stand just 5% off the all-time highs, it sure doesn't feel like it. After two lousy weeks and Monday's big sell-off, when we finally hit the elusive 5% decline that took almost a year to happen, Monday's late reversal showed that once again, the “buy the dip” crowd will wade into even the largest of sell-offs ... | Hedge Funds Dump Stocks: Move to These 5 Big Dividend Winners Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-09-21 13:53:09 | https://www.zacks.com/stock/news/1799090/abbvie-abbv-files-for-skyrizi-in-crohn-s-disease-with-fda | AbbVie (ABBV) submits a regulatory application in the United States, seeking approval for Skyrizi in Crohn's disease. | AbbVie (ABBV) Files for Skyrizi in Crohn's Disease With FDA | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-09-20 19:10:26 | https://www.zacks.com/stock/news/1798617/abbvie-abbv-stock-moves-1-23-what-you-should-know | AbbVie (ABBV) closed the most recent trading day at $106.40, moving -1.23% from the previous trading session. | AbbVie (ABBV) Stock Moves -1.23%: What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2021-09-20 14:32:57 | https://investorplace.com/2021/09/abbv-stock-is-worth-28-more-based-on-impressive-dividends/ | AbbVie is still cheap despite its gains and has an attractive prospective yield. ABBV stock trades for less than 8x next year's earnings with a prospective 5.3% yield, making it 28.5% undervalued. | AbbVie Is Worth 28% More Based on Impressive Dividends | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-09-20 09:10:00 | https://www.prnewswire.com/news-releases/abbvie-submits-regulatory-application-to-fda-for-risankizumab-rzaa-skyrizi-for-the-treatment-of-patients-16-years-and-older-with-moderate-to-severe-crohns-disease-301380440.html | NORTH CHICAGO, Ill., Sept. 20, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for risankizumab-rzaa (600 mg intravenous (IV) induction and 360 mg subcutaneous (SC) maintenance therapy), an interleukin-23 (IL-2... | AbbVie Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI®) for the Treatment of Patients 16 Years and Older with Moderate to Severe Crohn's Disease | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-09-19 11:01:00 | https://www.fool.com/investing/2021/09/19/is-abbvie-a-bad-news-buy/ | Probably so -- for some investors. | Is AbbVie a Bad News Buy? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-09-18 11:53:13 | https://seekingalpha.com/article/4455976-3-ideal-dogs-brighten-buffetts-29-september-dividend-holdings | 3 Ideal Dogs Brighten Buffett's 29 September Dividend Holdings | 3 Ideal Dogs Brighten Buffett's 29 September Dividend Holdings | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-09-18 05:57:00 | https://www.fool.com/investing/2021/09/18/abbvies-pain-is-sanofis-and-regenerons-gain/ | There are both winners and losers with the new Food and Drug Administration restrictions on JAK inhibitors. | AbbVie's Pain Is Sanofi's and Regeneron's Gain | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-09-17 10:42:16 | https://www.zacks.com/stock/news/1797823/abbvie-abbv-files-for-rinvoq-in-ulcerative-colitis-in-us-eu | AbbVie (ABBV) files regulatory applications to the FDA and the EMA, seeking approval for a new indication of Rinvoq - active ulcerative colitis. | AbbVie (ABBV) Files for Rinvoq in Ulcerative Colitis in US & EU | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-09-16 12:42:42 | https://www.benzinga.com/general/biotech/21/09/22969049/abbvie-submits-upadacitinib-applications-in-us-europe-for-ulcerative-colitis | AbbVie Inc (NYSE: ABBV) has submitted applications seeking approval for upadacitinib (15 mg and 30 mg (maintenance dose) and 45 mg (induction dose)) for active ulcerative colitis to FDA and the European Medicines Agency (EMA). Related Content: FDA Hits JAK inhibitors With Heart Safety, Cancer Warnings: All You Need T... | AbbVie Submits Upadacitinib Applications In US, Europe For Ulcerative Colitis | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-09-16 09:05:00 | https://www.fool.com/investing/2021/09/16/2-embarrassingly-cheap-dividend-stocks-to-buy/ | The market has written off these two high-quality stocks, but both could complement an income investor's portfolio. | 2 Embarrassingly Cheap Dividend Stocks to Buy | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-09-15 23:35:32 | https://seekingalpha.com/article/4455481-2-yield-traps-to-avoid-and-2-high-yield-aristocrats-for-retirees | 2 Yield Traps To Avoid And 2 High-Yield Aristocrats That Will Make Retirees Overjoyed | 2 Yield Traps To Avoid And 2 High-Yield Aristocrats That Will Make Retirees Overjoyed | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-09-15 13:22:09 | https://seekingalpha.com/article/4455393-abbvie-inc-abbv-ceo-rich-gonzalez-presents-morgan-stanley-virtual-19th-annual-global | AbbVie Inc. (ABBV) CEO Rich Gonzalez Presents at Morgan Stanley Virtual 19th Annual Global Healthcare Conference (Transcript) | AbbVie Inc. (ABBV) CEO Rich Gonzalez Presents at Morgan Stanley Virtual 19th Annual Global Healthcare Conference (Transcript) | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-09-15 11:00:32 | https://www.fool.com/investing/2021/09/15/is-abbvies-49-dividend-yield-safe/ | Should investors pick up the stock after its recent sell-off? | Is AbbVie's 4.9% Dividend Yield Safe? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-09-14 19:06:25 | https://www.zacks.com/stock/news/1796391/abbvie-abbv-dips-more-than-broader-markets-what-you-should-know | AbbVie (ABBV) closed the most recent trading day at $106.48, moving -0.93% from the previous trading session. | AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-09-14 12:14:21 | https://www.zacks.com/stock/news/1796135/abbvie-abbv-to-co-develop-regenxbio-eye-disease-gene-therapy | AbbVie (ABBV) is set to co-develop Regenexbio's investigational gene therapy for chronic retinal diseases like wet age-related macular degeneration. | AbbVie (ABBV) to Co-Develop Regenxbio Eye Disease Gene Therapy | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-09-14 12:14:14 | https://www.zacks.com/stock/news/1796141/regenxbio-rgnx-stock-up-on-collaboration-deal-with-abbvie | REGENXBIO (RGNX) enters into a strategic partnership with AbbVie to co-develop and commercialize RGX-314, a potential gene therapy for retinal indications. Resultantly, REGENXBIO's share price surges. | REGENXBIO (RGNX) Stock Up on Collaboration Deal With AbbVie | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-09-14 10:28:22 | https://seekingalpha.com/article/4455110-abbvie-the-fda-decision-on-rinvoq-likely-means-trouble | AbbVie is a premier dividend stock with a superior and safe dividend. The business has been firing on all cylinders but a recent FDA decision likely spells trouble. | AbbVie: The FDA Decision On RINVOQ Likely Means Trouble | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2021-09-13 18:26:56 | https://www.gurufocus.com/news/1522886/eyes-have-it-in-abbvie-deal-with-regenxbio | To expand its footprint in eye care, AbbVie Inc.( ABBV , Financial) has struck a billion-dollar deal to gain access to a gene therapy used to treat several common kinds of eye disease. The Chicago-area pharma giant announced Monday that it will be collaborating with Regenxbio Inc. ( RGNX , Financial) on the Maryland-ba... | Eyes Have It in AbbVie Deal With Regenxbio | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-09-13 08:39:25 | https://www.benzinga.com/general/biotech/21/09/22905034/abbvie-regenxbio-ink-1-75b-retinal-gene-therapy-collaboration | AbbVie Inc (NYSE: ABBV) and Regenxbio Inc (NASDAQ: RGNX) have partnered to develop and commercialize RGX-314, potential one-time gene therapy for wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR), and other chronic retinal diseases. RGX-314 is currently being evaluated in patients with wet AMD ... | AbbVie, RegenXBio Ink $1.75B Retinal Gene Therapy Collaboration | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Market Watch | 2021-09-13 08:25:15 | https://www.marketwatch.com/story/abbvies-deal-to-develop-regenxbios-investigational-gene-therapy-could-be-worth-18-billion-2021-09-13 | Shares of AbbVie Inc. ABBV, -0.55% were up 0.8% in premarket trading on Monday after the drug maker announced a potential billion-dollar deal to develop and commercialize Regenxbio Inc.'s RGNX, -1.66% experimental gene therapy, which is being tested as a treatment for several eye diseases. Regenxbio's stock jumped 18.2... | AbbVie's deal to develop Regenxbio's investigational gene therapy could be worth $1.8 billion | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-09-10 10:27:00 | https://www.prnewswire.com/news-releases/abbvie-declares-quarterly-dividend-301373397.html | NORTH CHICAGO, Ill., Sept. 10, 2021 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.30 per share. | AbbVie Declares Quarterly Dividend | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-09-10 09:55:19 | https://www.fool.com/investing/2021/09/10/3-stocks-to-watch-in-september/ | Even with the market regularly setting new highs, it could pay to keep an eye on these potential winners. | 3 Stocks to Watch in September | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-09-10 09:00:00 | https://www.prnewswire.com/news-releases/abbvie-to-highlight-its-leadership-in-movement-disorders-at-the-international-parkinson-and-movement-disorder-society-virtual-congress-2021-301373043.html | NORTH CHICAGO, Ill., Sept. 10, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that data from its robust neuroscience portfolio will be presented at the International Parkinson and Movement Disorder Society (MDS) Virtual Congress 2021, taking place September 17-22. | AbbVie to Highlight Its Leadership in Movement Disorders at the International Parkinson and Movement Disorder Society Virtual Congress 2021 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-09-09 11:30:00 | https://www.fool.com/investing/2021/09/09/could-this-label-expansion-be-a-blockbuster-for-ab/ | The EC's approval of Rinvoq for moderate to severe eczema is another step in the right direction for the company. | Could This Label Expansion Be a Blockbuster for AbbVie's Shareholders? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-09-08 23:52:57 | https://seekingalpha.com/article/4454160-13-ideally-priced-most-reliable-dividends-on-earth-september | The 13 Ideally Priced Most Reliable Dividends On Earth For September | The 13 Ideally Priced Most Reliable Dividends On Earth For September | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-09-08 19:24:26 | https://www.zacks.com/stock/news/1793915/abbvie-abbv-gains-as-market-dips-what-you-should-know | AbbVie (ABBV) closed at $110.36 in the latest trading session, marking a +1.22% move from the prior day. | AbbVie (ABBV) Gains As Market Dips: What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-09-08 09:10:00 | https://www.prnewswire.com/news-releases/abbvie-to-present-data-from-its-migraine-portfolio-at-the-2021-international-headache-congress-301371379.html | NORTH CHICAGO, Ill., Sept. 8, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that data from its migraine portfolio will be presented at the International Headache Congress 2021, held jointly this year by the International Headache Society and the European Headache Federation, from September 8-12. | AbbVie to Present Data From Its Migraine Portfolio at the 2021 International Headache Congress | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Forbes | 2021-09-07 07:30:00 | https://www.forbes.com/sites/greatspeculations/2021/09/07/should-you-buy-abbvie-stock-after-the-recent-7-fall/ | The stock price of AbbVie reached its 52-week high of around $121 just last week before a recent sell-off in ABBV stock, especially after the U.S. FDA stated that all janus kinase inhibitors approved for arthritis treatment should carry a heart-risk warning on the label - sending the stock to lower. | Should You Buy AbbVie Stock After The Recent 7% Fall? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-09-06 02:55:00 | https://seekingalpha.com/article/4453709-dividend-income-summary-lanny-august-2021-summary | In August, my wife and I received a total of $1,307.71 of dividend income. We crossed one thousand dollars again in an off-month. Another strong month of dividend income, and the 4-digit mark is becoming more and more consistent. Despite the pandemic from COVID-19, dividend income continues to grow, due primarily to ad... | Dividend Income Summary: Lanny's August 2021 Summary | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Pulse2 | 2021-09-05 08:33:50 | https://pulse2.com/abbvie-nyse-abbv-stock-131-price-target-by-mizuho-securities/ | The shares of AbbVie Inc (NYSE: ABBV) have received a $131 price target by Mizuho Securities. These are the details. | ABBV Stock: $131 Price Target By Mizuho Securities | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
24/7 Wall Street | 2021-09-03 07:06:46 | https://247wallst.com/investing/2021/09/03/why-5-of-the-highest-yielding-dividend-aristocrats-may-be-the-safest-bet-for-rest-of-2021/ | While summer officially ends on September 22, the Labor Day weekend marks the end for traders and investors, as Wall Street looks to return to normal and get back to work next week. | Why 5 of the Highest-Yielding Dividend Aristocrats May Be the Safest Bet for Rest of 2021 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2021-09-02 13:34:14 | https://investorplace.com/2021/09/7-healthcare-stocks-to-buy-before-3-5-trillion-floods-in/ | Covid-19 showed us how rapid advances in medicine and technology could create significant growth opportunities for healthcare stocks. The post 7 Healthcare Stocks to Buy Before $3.5 Trillion Floods In appeared first on InvestorPlace. | 7 Healthcare Stocks to Buy Before $3.5 Trillion Floods In | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-09-02 10:39:16 | https://www.zacks.com/stock/news/1790266/fda-orders-warnings-on-pfizer-lilly-abbvie-jak-drug-labels | The FDA requires a heart-risk warning on the label of JAK inhibitor medicines, Pfizer's (PFE) Xeljanz/Xeljanz XR, Lilly (LLY)/Incyte's (INCY) Olumiant, and AbbVie's (ABBV) Rinvoq. | FDA Orders Warnings on Pfizer, Lilly, AbbVie JAK Drug Labels | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-09-02 06:02:00 | https://www.fool.com/investing/2021/09/02/3-biotech-stocks-that-are-too-cheap-to-ignore/ | You'll definitely want to check out these biotech bargains. | 3 Biotech Stocks That Are Too Cheap to Ignore | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-09-01 21:14:53 | https://seekingalpha.com/article/4453089-4-blue-chip-bargains-in-the-bio-pharma-space | Now is not the time to sell healthcare. Biopharma offers some of the highest quality bargains in the entire market right now. | 4 Blue Chip Bargains In The Biopharma Space | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-09-01 15:55:26 | https://www.fool.com/investing/2021/09/01/why-abbvie-is-down-more-than-7-today/ | The Food and Drug Administration is drawing reasonable conclusions, but not necessarily conclusions that matter much to consumers. | Why AbbVie Is Down More Than 7% Today | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2021-09-01 15:51:53 | https://www.youtube.com/watch?v=RhZPBKtIGko | The "Halftime Report" traders give their top picks to watch for the second half. | Final Trades: Abbvie, Wabtec, Freeport-McMoRan & more | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2021-08-31 13:41:24 | https://investorplace.com/2021/08/7-dividend-aristocrat-stocks-to-buy-in-september-for-gains-and-stability/ | The dividend aristocrat stocks are often looked over, but investors really should give them a look with their 10% plus returns and stability. The post 7 Dividend Aristocrat Stocks to Buy in September for Gains and Stability appeared first on InvestorPlace. | 7 Dividend Aristocrat Stocks to Buy in September for Gains and Stability | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-08-31 10:00:00 | https://www.fool.com/investing/2021/08/31/if-youre-retired-consider-buying-these-2-stocks/ | Reliable cash flows and a history of payout hikes should hold retirees in good stead. | If You're Retired, Consider Buying These 2 Stocks | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-08-30 14:59:57 | https://seekingalpha.com/article/4452627-abbvie-is-this-dividend-aristocrat-overbought-or-is-there-more-room-to-run | Investors are looking to add defensive, stable dividend stocks to their portfolio. | AbbVie: Is This Dividend Aristocrat Overbought Or Is There More Room To Run? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-08-30 10:16:36 | https://www.fool.com/investing/2021/08/30/does-the-pullback-in-this-pharma-stock-create-a-bu/ | Amgen continues to face the headwind of patient visits that are lower than before the pandemic. | Does the Pullback in This Pharma Stock Create a Buying Opportunity? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-08-29 06:48:00 | https://www.fool.com/investing/2021/08/29/could-these-clinical-results-mean-profit-for-abbvi/ | The pharma stock announced strong phase 3 results for atogepant in the preventive treatment of episodic migraine. | Could These Clinical Results Mean Profit for AbbVie Shareholders? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-08-28 06:06:00 | https://www.fool.com/investing/2021/08/28/5-high-yield-dividend-stocks-double-money-by-2029/ | These income stocks, with yields ranging from 4.4% to 10.3%, are investors' tickets to riches. | 5 High-Yield Dividend Stocks That Can Double Your Money by 2029 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-08-27 06:12:00 | https://www.fool.com/investing/2021/08/27/2-healthcare-stocks-that-could-make-you-richer/ | Income seekers and growth investors can both find plenty to like about these two top healthcare stocks. | 2 Healthcare Stocks That Could Make You Richer | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-08-27 05:52:00 | https://www.fool.com/investing/2021/08/27/this-warren-buffett-dividend-stock-is-still-dirt-c/ | The Oracle of Omaha has already made a great return from his investment in this big pharma stock. | This Warren Buffett Dividend Stock Is Still Dirt Cheap | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
MarijuanaStocks | 2021-08-26 10:20:51 | https://marijuanastocks.com/best-medical-marijuana-stocks-to-buy-in-2021-2-possible-long-term-investments-right-now/ | Could These Be Good Long Term Investments For Your Portfolio? The post Best Medical Marijuana Stocks To Buy In 2021? 2 Possible Long Term Investments Right Now appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™. | Best Medical Marijuana Stocks To Buy In 2021? 2 Possible Long Term Investments Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-08-26 05:55:00 | https://www.fool.com/investing/2021/08/26/3-pharma-stocks-to-buy-with-juicy-dividends/ | And there's more than just dividends to like with these big pharma stocks. | 3 Pharma Stocks to Buy With Juicy Dividends | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-08-25 23:21:24 | https://seekingalpha.com/article/4451870-10-high-yield-blue-chips-to-safely-double-your-retirement-income | 10 High-Yield Blue Chips To Safely Double Your Retirement Income | 10 High-Yield Blue Chips To Safely Double Your Retirement Income | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-08-25 11:34:32 | https://www.zacks.com/stock/news/1786468/abbvie-s-abbv-rinvoq-gets-approval-for-eczema-in-europe | AbbVie's (ABBV) European approval for Rinvoq for atopic dermatitis marks the fourth EC-approved indication for the JAK inhibitor drug. | AbbVie's (ABBV) Rinvoq Gets Approval for Eczema in Europe | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-08-24 08:00:00 | https://www.prnewswire.com/news-releases/european-commission-approves-rinvoq-upadacitinib-as-first-jak-inhibitor-in-the-european-union-for-the-treatment-of-both-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis-301361058.html | NORTH CHICAGO, Ill., Aug. 24, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the European Commission (EC) approved RINVOQ® (upadacitinib), an oral, selective and reversible JAK inhibitor, for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates ... | European Commission Approves RINVOQ® (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-08-23 13:00:12 | https://www.zacks.com/stock/news/1785432/why-abbvie-abbv-is-a-top-dividend-stock-for-your-portfolio | Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? | Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-08-21 11:36:00 | https://www.fool.com/investing/2021/08/21/3-boring-healthcare-stocks-everyone-should-own/ | These pharmaceutical giants offer strong, dependable dividends and the size to weather the market's ups and downs. | 3 Boring Healthcare Stocks Everyone Should Own | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-08-20 19:10:00 | https://seekingalpha.com/article/4450988-abbvie-dividend-stock-buy-dividend-stock-analysis | The S&P 500 continues to trend higher and set record highs, even though we've had a few down days recently. Despite the record highs, I will always continue to search for undervalued dividend stocks to buy. | AbbVie: A Dividend Stock To Buy? - Dividend Stock Analysis | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-08-20 07:15:00 | https://seekingalpha.com/article/4450785-dividend-aristocrats-5-to-buy-and-5-to-avoid | Dividend Aristocrats: 5 To Buy And 5 To Avoid | Dividend Aristocrats: 5 To Buy And 5 To Avoid | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-08-19 08:06:54 | https://seekingalpha.com/article/4450592-abbvie-inc-bull-thesis-strengthened | My last article analyzed AbbVie Inc. (ABBV) under the framework of perpetual growth and Buffett's 10x Pretax Rule. | AbbVie Inc.: Bull Thesis Strengthened By Marginal ROCE Results | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-08-18 17:28:00 | https://www.prnewswire.com/news-releases/new-england-journal-of-medicine-publishes-12-week-results-from-study-evaluating-atogepant-for-the-preventive-treatment-of-migraine-301358432.html | NORTH CHICAGO, Ill., Aug. 18, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the New England Journal of Medicine (NEJM) has published 12-week results from the Phase 3 ADVANCE trial evaluating atogepant for the preventive treatment of migraine in adults who meet criteria for episodic migraine. | New England Journal of Medicine Publishes 12-Week Results from Study Evaluating Atogepant for the Preventive Treatment of Migraine | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-08-18 13:05:25 | https://seekingalpha.com/article/4450411-build-your-dividend-factory-2-no-brainer-swans-to-buy-now | Build Your Dividend Factory: 2 'No Brainer' SWANs To Buy Now | Build Your Dividend Factory: 2 'No Brainer' SWANs To Buy Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2021-08-17 15:04:09 | https://investorplace.com/2021/08/7-buffett-stocks-to-buy-and-sell-if-you-want-to-be-like-berkshire/ | Buffett stocks are a hot topic among investors as they look to go long on some fresh plays. Kroger and Aon are among Berkshire's favorites. | 7 Buffett Stocks to Buy (and Sell) if You Want to Be Like Berkshire | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2021-08-17 13:49:47 | https://www.youtube.com/watch?v=OEtHeZ7SY8E | The "Halftime Report" traders give their top picks to watch for the second half. | Final Trades: Estee Lauder, Chipotle, Abbvie & more | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2021-08-17 07:31:51 | https://www.youtube.com/watch?v=ouYdIv4N8vI | CNBC's Leslie Picker reports on where Berkshire Hathaway is selling and buying. | Berkshire Hathaway decreases stake in Merck, AbbVie, Bristol-Myers | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-08-17 06:28:00 | https://www.fool.com/investing/2021/08/17/could-abbvie-stock-help-you-retire-a-millionaire/ | It could be a good investment either way. | Could AbbVie Stock Help You Retire a Millionaire? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.